NEW DELHI: Sanofi Consumer Healthcare announced its successful listing on the BSE and NSE.The company has emerged as a distinct legal entity following its demerger from Sanofi India. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective June 1.
In alignment with Sanofi’s global strategy, SCHIL is now operating independently, with a dedicated focus on the consumer healthcare sector, a company statement said.
Himanshu Bakshi, managing director, Sanofi Consumer Healthcare said, “India’s consumer healthcare market has vast potential. Sanofi Consumer Healthcare getting listed on BSE and NSE, marks a critical milestone for us; one that is further expected to strengthen our position and drive sustainable growth within the Indian market.
Further, we remain committed to our mission, which is to make self-care as simple as it should be and empower our consumers to take control of their health’’.
The portfolio includes allergy, digestive wellness, pain care, and multivitamins with key brands like Allegra, DePURA, Avil, and Combiflam.
In alignment with Sanofi’s global strategy, SCHIL is now operating independently, with a dedicated focus on the consumer healthcare sector, a company statement said.
Himanshu Bakshi, managing director, Sanofi Consumer Healthcare said, “India’s consumer healthcare market has vast potential. Sanofi Consumer Healthcare getting listed on BSE and NSE, marks a critical milestone for us; one that is further expected to strengthen our position and drive sustainable growth within the Indian market.
Further, we remain committed to our mission, which is to make self-care as simple as it should be and empower our consumers to take control of their health’’.
The portfolio includes allergy, digestive wellness, pain care, and multivitamins with key brands like Allegra, DePURA, Avil, and Combiflam.
